|
Quince Therapeutics Inc (NASDAQ: QNCX) |
|
Quince Therapeutics Inc
QNCX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Quince Therapeutics Inc 's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.78 %
Quince Therapeutics Inc net loss increased from $0 millions, to $-15 millions in first quarter of 2025,
• More on QNCX's Growth
|
|
Quince Therapeutics Inc realized a net loss in trailing twelve months.
Quince Therapeutics Inc realized cash reduction of $ -0.32 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.45.
• More on QNCX's Valuation
|
|
|
|
|
Quince Therapeutics Inc realized net loss in trailing twelve months.
Quince Therapeutics Inc realized cash outflow of $ -0.32per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.45.
Quince Therapeutics Inc Price to Book Ratio is at 4.33 lower than Industry Avg. of 2026.67. and higher than S&P 500 Avg. of 0.01
• More on QNCX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com